Predictive Value of Post-Percutaneous Coronary Intervention Quantitative Flow Ratio for Vessel-Oriented Composite Endpoint

Table 1

Characteristics of included studies.

Studies	Year	Country	Data source	Follow-up(months)	Patients	Target vessel numbers	Age (years)	Male (%)	Hypertension (%)	Diabetes (%)	Smoke (%)	Hyperlipidemia (%)	LVEF (%)	Target vessel proportion			PCI type
														LAD (%)	LCX (%)	RCA (%)
Biscaglia et al. [1]	2019	Other countries	HAWKEYE study	21	602	751	68	74	74	23	19	56	NA	47	25	28	DES
Kogame [12]	2019	Other countries	SYNTAX II trial	24	393	771	66.6	92.6	75.4	29.7	14.7	77.1	58.3	45.7	31.5	22.8	DES
Tang et al. [13]	2021	China	Unregistered study	24	186	415	63.1	75.3	61.8	34.9	67.7	18.8	56.2	40.7	25.5	33.7	DES
Tang et al. [14]	2021	China	Unregistered study	12	177	185	68	81	NA	46	NA	NA	NA	50	20	30	DCB
Liu and Ding [15]	2021	China	DCB-ISR trial	12	169	169	62.5	76	73	41	23	34	60.66	48	15	37	DCB
Zhang [16]	2022	China	PANDA III trial	24	1805	2227	60.9	70.2	62	23.9	50.8	32	59.2	48.4	21.6	30	DES

LVEF, left ventricular ejection fraction; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; DES, drug-eluting stent; DCB, drug-coated balloon; NA, not available. Biscaglia et al.’s study was from Italy and Spain. Kogame et al.’s study was from the Netherlands, Japan, Poland, United Kingdom, Northern Ireland, and Spain. Hawkeye Study (ClinicalTrials.gov, NCT02811796); SYNTAX II Trial (ClinicalTrials.gov, NCT02015832); PANDA III Trial (ClinicalTrials.gov, NCT02017275).